Acadia Pharmaceuticals Inc. (ACAD) stock analysis
ACAD · Acadia Pharmaceuticals Inc.
Latest recorded price: USD 18.67
Model-estimated fair value: USD 6.56. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Biotechnology
At $18.67, ACAD trades 184.6% above the model's base-case value of $6.56. Using FCFF DCF, the model estimates $6.32 in the conservative case and $6.95 in the optimistic case, with a valuation confidence score of 55/100. About 75% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 27.5%, free cash flow margin 9.8%, ROIC 33.0%. The model flags 1 risk signal for this company.
Similar companies in Healthcare
- ADMA Biologics, Inc. (ADMA)
- Agios Pharmaceuticals, Inc. (AGIO)
- Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
- AnaptysBio, Inc. - Common Stock (ANAB)
- Arrowhead Pharmaceuticals, Inc. - Common Stock (ARWR)
- Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
- Axsome Therapeutics, Inc. - Common Stock (AXSM)
- BridgeBio Pharma, Inc. - Common Stock (BBIO)